

## SYNERGISTIC APPROACH FOR **GREATER LDL-C REDUCTION**



**In High Risk ASCVD Patients**

<sup>Rx</sup> Diet, Exercise &

# **Roswow™-EZ** <sup>10</sup> <sup>20</sup> <sup>40</sup>

Rosuvastatin 10/20/40 mg + Ezetimibe 10 mg Tablets





## Background

\* **Statins** remain the cornerstone therapy for the management of hypercholesterolemia. However, in many patients, statin monotherapy is insufficient to achieve optimal lipid targets. Combination therapy becomes necessary when LDL-C remains inadequately controlled. Adding ezetimibe to statin therapy has been shown to significantly improve goal attainment of guideline-recommended cholesterol levels while also enabling the use of lower statin doses an important advantage for patients who are prone to dose-related adverse effects of statins. **Ezetimibe**, at its standard dose of 10 mg once daily, reduces LDL-C by approximately 15–20% as monotherapy. When combined with a statin, its lipid-lowering efficacy is enhanced synergistically. Therefore, the fixed-dose combination of rosuvastatin and ezetimibe provides an effective strategy for patients in whom maximally tolerated statin therapy fails to sufficiently reduce LDL-C.

## Product Description

- \* **ROSWOW-EZ combines two complementary lipid-lowering agents:**
- \* Rosuvastatin, a selective and potent HMG-CoA reductase inhibitor.
- \* Ezetimibe, a cholesterol absorption inhibitor acting at the intestinal level.

## Available strengths

- \* **ROSWOW-EZ 10:** Rosuvastatin 10 mg + Ezetimibe 10 mg
- \* **ROSWOW-EZ 20:** Rosuvastatin 20 mg + Ezetimibe 10 mg
- \* **ROSWOW-EZ 40:** Rosuvastatin 40 mg + Ezetimibe 10 mg

## Indication

- \* **ROSWOW-EZ (10/20/ 40 mg)** is indicated as an adjunct to diet & exercise in high risk ASCVD patients.

## Mechanism of Action

- \* **Rosuvastatin:** Acts by competitively inhibiting the enzyme HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, thereby upregulating LDL receptors and enhancing clearance of LDL-C from circulation.
- \* **Ezetimibe:** Targets the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1) in the brush border of the small intestine, inhibiting dietary and biliary cholesterol absorption. This leads to reduced delivery of intestinal cholesterol to the liver, decreased hepatic cholesterol stores, and enhanced clearance of circulating LDL-C.

## Dosage & Administration

- \* The recommended dose of **ROSWOW-EZ 10/20/ 40** is one tablet once daily orally. In patients with severe renal impairment not on hemodialysis, the dosage should not exceed Rosuvastatin 10 mg + Ezetimibe 10 mg once daily.
- \* No dose adjustments are required in patients with mild to moderate renal impairment.

### References:

1. J Thorac Dis. 2017 May;9(5):1226-1233
2. Clin Ther. 2017 Jan;39(1):107-117